Results 41 to 50 of about 92,728 (309)
Outcomes of dietitian involvement with leukemia patients receiving total parenteral nutrition [PDF]
, 2002 Plan BThere is an increasing need for justification of medical nutrition therapy given by the dietitian. With health care costs escalating rapidly, practitioners need to demonstrate that they can improve patient outcomes.
Mattson, Christine
core
FEBS Open Bio, EarlyView.Matrix metalloproteinase‐9 (MMP9) drives ovarian cancer progression. Using MMP9‐null cells (M9‐KO) created from ovarian cancer cells, we found MMP9 loss did not block Epidermal Growth Factor (EGF)‐driven E‐cadherin dissolution or EMT but delayed and reduced EGF‐driven membrane protrusions. Transient MMP9 re‐expression drove membrane protrusion.
Claire Strauel +8 more
wiley +1 more source
FEBS Open Bio, EarlyView.Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar +4 more
wiley +1 more source
Haematologica, 2012 Background A subset of patients with fludarabine-resistant chronic lymphocytic leukemia has previously been shown to express elevated intracellular levels of the concentrative high-affinity fludarabine transporter hCNT3, without any detectable related ...
Paula X. Fernández-Calotti +3 more
doaj +1 more source
Role of ofatumumab in treatment of chronic lymphocytic leukemia
, 2011 Marays Veliz, Javier Pinilla-IbarzH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAAbstract: The management of chronic lymphocytic leukemia (CLL) has dramatically improved in the past decade with the addition of anti-CD20 monoclonal ...
Pinilla-Ibarz J +3 more
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi +5 more
wiley +1 more source
Haematologica, 2015 Lenalidomide is an immunomodulatory agent clinically active in chronic lymphocytic leukemia patients. The specific mechanism of action is still undefined, but includes modulation of the microenvironment.
Stefania Fiorcari +11 more
doaj +1 more source
Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro +6 more
wiley +1 more source
Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia [PDF]
, 2006 The aim of this multicenter GIMEMA study was to correlate autoimmune complications (AIC) in B-cell chronic lymphocytic leukemia (B-CLL) with stage and therapy.
A. Ambrosetti +19 more
core
A Case of Hodgkin Transformation of Chronic Lymphocytic Leukemia
, 2016 Richter’s transformation is a serious complication of chronic lymphocytic leukemia. We present a patient with Hodgkin transformation of chronic lymphocytic leukemia. This patient was admitted to our clinic with the complaints of weakness and fatigue. She
İlhami Kiki +5 more
core +1 more source